written on 07.04.2014
Tags:
,

Roche jumps into epigenetics with deal for Oryzon's leukemia hopeful

TAGS: ,

pRED has struck its first epigenetics deal, with a $500 million-plus potential payoff for Oryzon and its orphan cancer blocker ORY-1001.

Latest Report